

Company name Intragel Therapeutics * Website <https://www.intra-gel.com/> *

CEO name Peter Siman, PhD

CATEGORY: Biotech/Pharma *

ABSTRACT

Transforming Oncology Through Long-Acting Injectable Therapies

IntraGel Therapeutics is a clinical-stage biotechnology company developing SRGel, a long-acting injectable platform enabling sustained and controlled drug release from a single administration. The platform addresses key limitations across oncology, endocrinology, and inflammatory diseases, where short drug half-life, systemic toxicity, and frequent dosing reduce efficacy and patient adherence. SRGel is a solvent-free, hydrophobic depot that supports high drug loading and tunable release over weeks to months, and is compatible with small molecules, peptides, and biologics for both localized and systemic delivery.

The lead program, TumoCure (cisplatin-SRGel), has been evaluated in a Phase 1 study in advanced locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN), including a salvage population of unresectable, chemotherapy-unfit, and radioresistant patients who exhausted standard treatment options. The study demonstrated encouraging tumor reduction and a favorable safety profile, with no drug-related serious adverse events (ClinicalTrials.gov Identifier: NCT05200650). Localized delivery enabled high intratumoral drug exposure while reducing systemic toxicity, supporting an improved therapeutic index.

IntraGel is preparing to initiate a Phase 2 study in elderly LA-SCCHN patients who are unfit for systemic cisplatin, have unresectable disease, and are candidates for radiotherapy (IMRT), with the goal of improving progression-free and overall survival in this high unmet-need population.

While intratumoral administration represents a clinically validated application, SRGel is broadly applicable across additional routes, including subcutaneous and intramuscular delivery, enabling long-acting therapies across multiple modalities and indications. This positions the platform as a versatile solution for improving drug exposure and patient adherence beyond oncology. Hence, IntraGel's business strategy combines internal pipeline development with a partnership-driven model.

With a signed term sheet from a strategic investor, IntraGel is raising a \$25M Series A to advance its oncology program, expand platform applications, and support development of a long-acting GLP-1 analogue targeting extended dosing intervals to improve patient adherence.